选择性雌激素受体调节剂的遗传毒性

Genetic toxicity of selective estrogen receptor modulators

文章的目的是回顾一些主要的选择性雌激素受体调节剂(包括克罗米芬、他莫昔芬、托瑞米芬、雷洛昔芬)的遗传毒性。这些药物被用于高风险女性不孕症的治疗和乳腺癌的预防。然而,一些研究表明他莫昔芬是一种具有遗传毒性的试剂,而且与子宫内膜癌的形成有关;他莫昔芬在大多数的试验中被发现是具有遗传毒性的;由已发表的报告表明,托瑞米芬是弱的基因毒性剂;目前,人们对雷洛昔芬的遗传毒性知之甚少,需要对其进行进一步的遗传毒性研究。

the purpose of this article is to review some of the main selective estrogen receptor modulators（including clomiphene, tamoxifen, toremifene, raloxifene） genetic toxicity. These drugs are used for high- risk women of infertility treatment and prevention of breast cancer. However, some studies have shown that tamoxifen is a genetic toxicity reagents and is related to the formation of endometrial cancer. Tamoxifen were found to be a genetic toxicity in most of the trials.The published reports suggest that toremifene is a weak genotoxic agent.Now,people have known little about the genetic toxicity of raloxifene and further genetic toxicity studies are needed.